ALB and diabetic kidney disease: A randomized placebo-controlled clinical trial on allogeneic mesenchymal precursor cells (MPCs) administration in DKD patients found that there was no significant difference in the ratio of urinary creatinine–albumin, serum creatinine, and HbA1c in the test group compared to placebo [120].